The aim of this study is to evaluate the performance of a new rapid quantitative point-of-care commercially available device from BluSense Diagnostics, based on the SARS-CoV-2 trimeric spike protein, ViroTrack Sero COVID-19 Total Ab, with two CLIA laboratory-based immunoassays from Diasorin, LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 Trimeric S IgG assay. Here, CHMP5 is linked to COVID-19.